These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25031751)

  • 1. S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil.
    Lv F; Liu X; Wang B; Guo H; Li J; Shen L; Jin M
    Int J Clin Exp Pathol; 2014; 7(6):3293-8. PubMed ID: 25031751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil.
    Lv F; Liu X; Wang B; Guo H; Li J; Shen L; Jin M
    Int J Clin Exp Pathol; 2014; 7(7):4274-9. PubMed ID: 25120809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.
    Takahari D; Shimada Y; Takeshita S; Nishitani H; Takashima A; Okita N; Hirashima Y; Kato K; Hamaguchi T; Yamada Y; Shirao K
    Gastric Cancer; 2010 Aug; 13(3):186-90. PubMed ID: 20820988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).
    Ono A; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yasui H; Yamazaki K; Yoshino T; Taku K; Kojima T
    Jpn J Clin Oncol; 2009 May; 39(5):332-5. PubMed ID: 19318372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
    Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
    Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
    Ajani JA; Buyse M; Lichinitser M; Gorbunova V; Bodoky G; Douillard JY; Cascinu S; Heinemann V; Zaucha R; Carrato A; Ferry D; Moiseyenko V
    Eur J Cancer; 2013 Nov; 49(17):3616-24. PubMed ID: 23899532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
    Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.
    Iizumi S; Takashima A; Narita Y; Tajika M; Muro K; Kawai S; Yasui H; Matsushima T; Takahari D; Nagashima K; Boku N
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):575-582. PubMed ID: 28730292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
    Koizumi W; Tanabe S; Azuma M; Ishido K; Nishimura K; Sasaki T; Nakatani K; Higuchi K; Nakayama N; Katada C
    Int J Cancer; 2010 Jan; 126(1):162-70. PubMed ID: 19588501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
    Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
    Ajani JA; Rodriguez W; Bodoky G; Moiseyenko V; Lichinitser M; Gorbunova V; Vynnychenko I; Garin A; Lang I; Falcon S
    J Clin Oncol; 2010 Mar; 28(9):1547-53. PubMed ID: 20159816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis.
    Nakayama I; Chin K; Matsushima T; Takahari D; Ogura M; Shinozaki E; Suenaga M; Ozaka M; Wakatsuki T; Ichimura T; Hiroki O; Yamaguchi K
    Int J Clin Oncol; 2017 Dec; 22(6):1060-1068. PubMed ID: 28748355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.
    Li YH; Qiu MZ; Xu JM; Sun GP; Lu HS; Liu YP; Zhong MZ; Zhang HL; Yu SY; Li W; Hu XH; Wang JJ; Cheng Y; Zhou JT; Guo ZQ; Guan ZG; Xu RH
    Oncotarget; 2015 Oct; 6(33):35107-15. PubMed ID: 26439700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
    Kataoka H; Mori Y; Shimura T; Nishie H; Natsume M; Mochizuki H; Hirata Y; Sobue S; Mizushima T; Sano H; Mizuno Y; Nakamura M; Hirano A; Tsuchida K; Adachi K; Seno K; Kitagawa M; Kawai T; Joh T
    Cancer Chemother Pharmacol; 2016 May; 77(5):957-62. PubMed ID: 27002325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer.
    Sasaki Y; Iwasa S; Okazaki S; Goto M; Kojima Y; Naganuma A; Nagashima K; Nagai Y; Hirano H; Honma Y; Takashima A; Kato K; Hamaguchi T
    Gastric Cancer; 2018 May; 21(3):439-445. PubMed ID: 28766263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer.
    Wu Q; Fu Y; Wen W; Xi T; Zhao G
    J BUON; 2020; 25(2):987-994. PubMed ID: 32521896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: a meta-analysis.
    Liu GF; Tang D; Li P; Wang S; Xu YX; Long AH; Zhou NL; Zhang LL; Chen J; Xiang XX
    World J Gastroenterol; 2014 Jan; 20(1):310-8. PubMed ID: 24415887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer.
    Choi IS; Lee KW; Kim KH; Kim YJ; Kim JH; Lee JS
    Med Oncol; 2010 Sep; 27(3):992-7. PubMed ID: 20077040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of gastric cancer in Asia: the missing link.
    Nishida T
    Lancet Oncol; 2009 Nov; 10(11):1027-8. PubMed ID: 19880057
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.